BeOne Medicines AG (ONC) Financial Statements

Executive TeamFinancials
SegmentsShareholders

BeOne Medicines financial statements at a glance

BeOne Medicines reported revenue of $5.34 billion for fiscal year 2025 (ended December 31, 2025), up 40.2% from fiscal year 2024. Net income was $286.93 million, a net margin of 5.4%.

At the end of fiscal year 2025 it had total assets of $8.19 billion, total liabilities of $3.83 billion and shareholders' equity of $4.36 billion, with cash and short-term investments of $4.55 billion and total debt of $1.09 billion.

Its operations brought in $1.13 billion of cash; capital spending was $266.53 million, leaving free cash flow of $861.05 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

ONC logo

BeOne Medicines AG

ONCSwitzerland
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
5.34B
Prev Year: 3.81B
YoY: +40.2%
Operating Revenue
6.79B
Prev Year: 4.79B
YoY: +41.8%
Cost of Revenue
668.54M
Prev Year: 594.09M
YoY: +12.5%
Gross Profit
4.67B
Prev Year: 3.22B
YoY: +45.3%
Operating Expense
4.23B
Prev Year: 3.78B
YoY: +11.7%
Selling General and Administrative
2.08B
Prev Year: 1.83B
YoY: +13.7%
Research and Development
2.15B
Prev Year: 1.95B
YoY: +9.9%
Operating Income
447.14M
Prev Year: -568.20M
YoY: +178.7%
Net Non Operating Interest Income Expense
12.27M
Prev Year: 47.84M
YoY: -74.3%
Non-operating Interest Income
70.50M
Prev Year: 47.84M
YoY: +47.4%
Non-operating Interest Expense
58.23M
Total Other Finance Cost
-
Other Income Expense
-42.55M
Prev Year: -12.64M
YoY: -236.7%
Other Non-operating Income (expense)
-42.55M
Prev Year: -12.64M
YoY: -236.7%
Gain on Sale of Securities
-
Pre-tax Income
416.85M
Prev Year: -533.00M
YoY: +178.2%
Provision for Income Taxes
129.92M
Prev Year: 111.78M
YoY: +16.2%
Net Income Common Stockholders
286.93M
Prev Year: -644.79M
YoY: +144.5%
Net Income
286.93M
Prev Year: -644.79M
YoY: +144.5%
Net Income Including Non-Controlling Interests
286.93M
Prev Year: -644.79M
YoY: +144.5%
Net Income from Continuing Operations
286.93M
Prev Year: -644.79M
YoY: +144.5%
Net Income from Continuing and Discontinued Operation
286.93M
Prev Year: -644.79M
YoY: +144.5%
Normalized Income
286.93M
Prev Year: -644.79M
YoY: +144.5%
Basic EPS
-
Prev Year: -0.47
Interest Income
70.50M
Prev Year: 47.84M
YoY: +47.4%
Diluted EPS
-
Prev Year: -0.47
Interest Expense
58.23M
Weighted Average Shares (basic)
-
Prev Year: 1.37B
Net Interest Income
12.27M
Prev Year: 47.84M
YoY: -74.3%
Weighted Average Shares (diluted)
-
Prev Year: 1.37B
EBIT
475.09M
Prev Year: -568.20M
YoY: +183.6%
EBITDA
616.77M
Prev Year: -396.44M
YoY: +255.6%
Reconciled Cost of Revenue
668.54M
Prev Year: 594.09M
YoY: +12.5%
Reconciled Depreciation
141.69M
Prev Year: 171.76M
YoY: -17.5%
Net Income from Continuing Operation Net Minority Interest
286.93M
Prev Year: -644.79M
YoY: +144.5%
Normalized EBITDA
616.77M
Prev Year: -396.44M
YoY: +255.6%
Tax Rate for Calcs
0.312
Prev Year: 0
Total Expenses
4.90B
Prev Year: 4.38B
YoY: +11.8%
Total Operating Income as Reported
447.14M
Prev Year: -568.20M
YoY: +178.7%
Diluted NI Available to Com Stockholders
286.93M
Prev Year: -644.79M
YoY: +144.5%
Total Unusual Items Excluding Goodwill
-
Values in USD

BeOne Medicines key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$5.3B$3.8B$2.5B$1.4B$1.2B
Gross profit$4.7B$3.2B$2.1B$1.1B$1.0B
Operating income$447.1M-$568.2M-$1.2B-$1.8B-$1.4B
Net income$286.9M-$644.8M-$881.7M-$2.0B-$1.5B
Diluted EPS–-$0.47-$0.65-$1.49-$1.17
Total assets$8.2B$5.9B$5.8B$6.4B$8.5B
Total liabilities$3.8B$2.6B$2.3B$2.0B$2.4B
Shareholders' equity$4.4B$3.3B$3.5B$4.4B$6.1B
Cash and short-term investments$4.5B$2.6B$3.2B$4.5B$6.6B
Total debt$1.1B$1.1B$930.2M$596.7M$694.6M
Operating cash flow$1.1B-$140.6M-$1.2B-$1.5B-$1.3B
Capital spending$266.5M$529.1M$596.3M$469.1M$314.9M
Free cash flow$861.1M-$669.8M-$1.8B-$2.0B-$1.6B

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was BeOne Medicines's revenue in fiscal year 2025?

$5.34 billion, up 40.2% from $3.81 billion in fiscal year 2024.

How much profit does BeOne Medicines make?

BeOne Medicines reported net income of $286.93 million for fiscal year 2025 (5.4% of revenue); operating income was $447.14 million.

How much cash and debt does BeOne Medicines have?

At the end of fiscal year 2025: cash and short-term investments of $4.55 billion and total debt of $1.09 billion.

What is BeOne Medicines's free cash flow?

$861.05 million in fiscal year 2025 (operating cash flow of $1.13 billion minus capital spending of $266.53 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube